Effect of concentrated growth factors on quality of life of patients undergoing implant therapy : a cohort study
Copyright 2020 Biolife Sas. www.biolifesas.org..
Pain, bad taste, and impaired daily activity after implant therapy are common sequelae. Concentrated growth factors (CGF) are a platelet concentrate with a favourable effect on wound healing, but there is still no evidence regarding its potential benefits for reducing postoperative pain and symptoms. Therefore, aim of this prospective comparative study was to determine the effect of CGF on quality of life (QoL) of patients after implant therapy. Fifty-two consecutive patients with one missing mandibular molar were included in the study and alternatively assigned to two groups. Control group received standard implant treatment, and test group received CGF associated with implants. Standard periapical radiographs were taken before and after procedure. Post-operative care consisted of 0.2% chlorhexidine digluconate solution twice daily for 10 days. A QoL questionnaire (OHIP-14) for bad taste, pain and limitation in daily activities was filled and returned one week post-operatively. Daily pain was also assessed through Visual Analogue Scale (VAS) on a 1-100 scale. Parametric test (chi-square) was performed to compare the results of the questionnaire between the two groups using STATA statistical software. All patients correctly filled and returned the questionnaire. Significantly higher proportions of patients of test group reported no bad taste, pain, and limited activity, (24/26, 13/26, and 25/26, respectively) respect to control. Postoperative pain with VAS score was significantly lower in the test group on day 1, 2, and 3 as compared to control. CGF positively influenced QoL when associated with implant rehabilitation of mandibular molars, minimizing post-operative discomfort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of biological regulators and homeostatic agents - 35(2021), 2 Suppl. 1 vom: 27. März, Seite 147-154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Taschieri, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ageusia |
|---|
| Anmerkungen: |
Date Completed 21.07.2021 Date Revised 21.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.23812/21-2supp1-14 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328266132 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328266132 | ||
| 003 | DE-627 | ||
| 005 | 20231225202606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23812/21-2supp1-14 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328266132 | ||
| 035 | |a (NLM)34281311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Taschieri, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of concentrated growth factors on quality of life of patients undergoing implant therapy |b a cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2021 | ||
| 500 | |a Date Revised 21.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2020 Biolife Sas. www.biolifesas.org. | ||
| 520 | |a Pain, bad taste, and impaired daily activity after implant therapy are common sequelae. Concentrated growth factors (CGF) are a platelet concentrate with a favourable effect on wound healing, but there is still no evidence regarding its potential benefits for reducing postoperative pain and symptoms. Therefore, aim of this prospective comparative study was to determine the effect of CGF on quality of life (QoL) of patients after implant therapy. Fifty-two consecutive patients with one missing mandibular molar were included in the study and alternatively assigned to two groups. Control group received standard implant treatment, and test group received CGF associated with implants. Standard periapical radiographs were taken before and after procedure. Post-operative care consisted of 0.2% chlorhexidine digluconate solution twice daily for 10 days. A QoL questionnaire (OHIP-14) for bad taste, pain and limitation in daily activities was filled and returned one week post-operatively. Daily pain was also assessed through Visual Analogue Scale (VAS) on a 1-100 scale. Parametric test (chi-square) was performed to compare the results of the questionnaire between the two groups using STATA statistical software. All patients correctly filled and returned the questionnaire. Significantly higher proportions of patients of test group reported no bad taste, pain, and limited activity, (24/26, 13/26, and 25/26, respectively) respect to control. Postoperative pain with VAS score was significantly lower in the test group on day 1, 2, and 3 as compared to control. CGF positively influenced QoL when associated with implant rehabilitation of mandibular molars, minimizing post-operative discomfort | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a ageusia | |
| 650 | 4 | |a bad taste | |
| 650 | 4 | |a concentrated growth factor | |
| 650 | 4 | |a dysgeusia | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a patient reported outcome measures | |
| 650 | 4 | |a quality of life | |
| 700 | 1 | |a Khijmatgar, S |e verfasserin |4 aut | |
| 700 | 1 | |a Corbella, S |e verfasserin |4 aut | |
| 700 | 1 | |a Francetti, L |e verfasserin |4 aut | |
| 700 | 1 | |a Parrini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Del Fabbro, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biological regulators and homeostatic agents |d 1989 |g 35(2021), 2 Suppl. 1 vom: 27. März, Seite 147-154 |w (DE-627)NLM012600660 |x 0393-974X |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:2 Suppl. 1 |g day:27 |g month:03 |g pages:147-154 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23812/21-2supp1-14 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 2 Suppl. 1 |b 27 |c 03 |h 147-154 | ||